COVID-19 核酸扩增测试 (NAAT) 市场：管道报告2023 年最新版

NAAT 标靶并扩增 SARS-CoV-2 病毒的特定核酸序列。与抗原鑑定方法相比，NAAT 显示出更高的灵敏度。PCR 中使用多个目标来检测不同类型的 SARS-Cov-2。

本报告调查了COVID-19核酸扩增测试（NAAT）市场，提供了产品概述、正在开发的管道产品的趋势、处于不同开发阶段的产品的比较分析、正在进行的临床试验的资讯以及参与公司的资讯。我们提供有关最新趋势等的资讯。

目录

第一章 内容

第 2 章 简介

第三章 开发中产品

• COVID-19 核酸扩增检验 (NAAT) - 按开发阶段划分的管道产品
• COVID-19 核酸扩增检验 (NAAT) - 区域管线产品
• COVID-19 核酸扩增测试 (NAAT) - 按监管途径分类的管道产品
• COVID-19 核酸扩增检验 (NAAT) - 正在进行的临床试验

第 4 章 COVID-19 核酸扩增检验 (NAAT) - 公司正在开发的管道产品

• COVID-19 核酸扩增检测 (NAAT) 公司 - 按开发阶段划分的在研产品
• COVID-19 核酸扩增检验 (NAAT) - 按开发阶段划分的管道产品

第五章 COVID-19 核酸扩增检测（NAAT）公司与产品概述

• Age Labs AS 公司简介
• Chengdu One-Chip Biotechnology Co Ltd公司简介

第 6 章 COVID-19 核酸扩增检测 (NAAT) - 最新进展

第7章附录

Abstract

GlobalData's Medical Devices sector report, "COVID 19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the COVID 19 Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

NAAT involves amplification of specific nucleic acid sequences of SARS-CoV-2 virus by targeting specific nucleic acid sequences. NAAT exhibits better sensitivity in comparison to antigen identification methods. Multiple targets are used in PCR to detect the different types of SARS-Cov-2.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of COVID 19 Nucleic Acid Amplification Tests (NAATs) and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Overview

3 Products under Development

• 3.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• 3.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• 3.3 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• 3.4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials

4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products under Development by Companies

• 4.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
• 4.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development

5 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies and Product Overview

• 5.1 Age Labs AS Company Overview
  • 5.1.1 Age Labs AS Pipeline Products & Ongoing Clinical Trials Overview
• 5.2 Chengdu One-Chip Biotechnology Co Ltd Company Overview
  • 5.2.1 Chengdu One-Chip Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

6 COVID 19 Nucleic Acid Amplification Tests (NAATs)- Recent Developments

• 6.1 Nov 29, 2023: BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
• 6.2 Oct 30, 2023: Cepheid Receives 510(K) Clearance For Xpert Xpress CoV-2 Plus Test
• 6.3 Mar 17, 2023: When time matters, rapid point of care testing can support treatment decisions
• 6.4 Mar 15, 2023: Cepheid receives Health Canada Licence for Xpert Xpress CoV-2 plus

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer

List of Tables

List of Tables

• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
• COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• Glossary

List of Figures

List of Figures

• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials